Silexion Therapeutics Warrant
SLXNW
19 hedge funds and large institutions have $98.7K invested in Silexion Therapeutics Warrant in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
59% more capital invested
Capital invested by funds: $62K → $98.7K (+$36.7K)
1.37% more ownership
Funds ownership: 39.39% → 40.76% (+1.4%)
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.01K |
| 2 |
Goldman Sachs
New York
|
+$35 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$242 |
| 2 |
CS
Clear Street
New York
|
-$13 |
SLXNW Hedge Fund Activity: Q2 2026 in Review
19 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q2 2026, worth a combined $98.7K — up 59% from $62K a quarter earlier.
Fund positioning in SLXNW was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $2.01K. The largest seller was Saba Capital Management, exiting entirely with an estimated $242 sold.
- 19 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $98.7K of Silexion Therapeutics Warrant stock for Q2 2026, up 59% quarter-over-quarter.
- 1 fund opened new Silexion Therapeutics Warrant positions in Q2 2026 and 1 closed out, a net change of 0 holders.
- The largest Silexion Therapeutics Warrant buyer in Q2 2026 was Susquehanna International Group, an estimated $2.01K added.
- The largest Silexion Therapeutics Warrant seller in Q2 2026 was Saba Capital Management, an estimated $242 sold.
Based on aggregated 13F filings for Q2 2026.